Reviva Pharmaceuticals Holdings (RVPH) Return on Invested Capital (2023 - 2026)

Reviva Pharmaceuticals Holdings has reported Return on Invested Capital for 4 years, with the latest figure at 0.23% in Q1 2026.

• Quarterly Return on Invested Capital rose 5.0% year-over-year to 0.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.23% (up 5.0% YoY) and the FY2025 annual result came in at 0.47%, changed N/A from the prior year.
• Return on Invested Capital rose to 0.23% in Q1 2026 per RVPH's latest filing, from 0.26% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.23% in Q1 2026 and troughed at 0.5% in Q4 2024.
• A 4-year average of 0.37% and a median of 0.37% in 2023 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Return on Invested Capital dropped 14 bps in 2024, then rose 24 bps in 2025.
• Over 4 years, Return on Invested Capital stood at 0.35% in 2023, then slumped by 41 bps to 0.5% in 2024, then jumped by 47 bps to 0.26% in 2025, then gained by 14 bps to 0.23% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.23%, 0.26%, and 0.27% for Q1 2026, Q4 2025, and Q3 2025 respectively.